Pfizer Share Price
Sector: Major Drugs
4412.60 -43.65 (-0.98%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
4396.35
Today’s High
4498.75
52 Week Low
3742.90
52 Week High
6452.85
4413.20 -46.00 (-1.03%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
4400.00
Today’s High
4476.70
52 Week Low
3701.00
52 Week High
6451.15
Key Metrics
- Market Cap (In Cr) 20156.11
- Beta 0.46
- Div. Yield (%) 0.79
- P/B 5.62
- TTM P/E 39.26
- Sector P/E 24.4
- Open Price 4498.75
- Prev Close 4456.25
Pfizer Analysis
Price Analysis
-
1 Week3.84%
-
3 Months5.62%
-
6 Month-15.24%
-
YTD-16.44%
-
1 Year1.79%
Risk Meter
- 28% Low risk
- 28% Moderate risk
- 28% Balanced Risk
- 28% High risk
- 28% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 2
- 2
- 2
- 2
- Buy
- 0.00
- 0.00
- 0.00
- 0.00
- Hold
- 1
- 1
- 1
- 1
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 3
- 3
- 3
- 3
Pfizer Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 2193.17
- Selling/ General/ Admin Expenses Total
- 688.51
- Depreciation/ Amortization
- 62.28
- Other Operating Expenses Total
- 16.96
- Total Operating Expense
- 1601.81
- Operating Income
- 591.36
- Net Income Before Taxes
- 746.07
- Net Income
- 551.33
- Diluted Normalized EPS
- 119.72
- Period
- 2024
- Total Assets
- 4228.78
- Total Liabilities
- 633.24
- Total Equity
- 3595.54
- Tangible Book Valueper Share Common Eq
- 663.15
- Period
- 2024
- Cashfrom Operating Activities
- 256.84
- Cashfrom Investing Activities
- 53.7
- Cashfrom Financing Activities
- -235.14
- Net Changein Cash
- 75.4
- Period
- 2023
- Total Revenue
- 2424.76
- Selling/ General/ Admin Expenses Total
- 650.55
- Depreciation/ Amortization
- 104.02
- Other Operating Expenses Total
- 30.07
- Total Operating Expense
- 1680.32
- Operating Income
- 744.44
- Net Income Before Taxes
- 824.01
- Net Income
- 623.93
- Diluted Normalized EPS
- 130.83
- Period
- 2023
- Total Assets
- 4000.73
- Total Liabilities
- 793.43
- Total Equity
- 3207.3
- Tangible Book Valueper Share Common Eq
- 576.11
- Period
- 2023
- Cashfrom Operating Activities
- 355.68
- Cashfrom Investing Activities
- -36.05
- Cashfrom Financing Activities
- -345.79
- Net Changein Cash
- -26.16
- Period
- 2022
- Total Revenue
- 2610.99
- Selling/ General/ Admin Expenses Total
- 740.31
- Depreciation/ Amortization
- 113.61
- Other Operating Expenses Total
- 18.38
- Total Operating Expense
- 1879.37
- Operating Income
- 731.62
- Net Income Before Taxes
- 772.89
- Net Income
- 612.56
- Diluted Normalized EPS
- 133.1
- Period
- 2022
- Total Assets
- 3900.51
- Total Liabilities
- 1036.1
- Total Equity
- 2864.41
- Tangible Book Valueper Share Common Eq
- 490.16
- Period
- 2022
- Cashfrom Operating Activities
- 667.08
- Cashfrom Investing Activities
- -575.02
- Cashfrom Financing Activities
- -180.51
- Net Changein Cash
- -88.45
- Period
- 2021
- Total Revenue
- 2238.55
- Selling/ General/ Admin Expenses Total
- 633.05
- Depreciation/ Amortization
- 108.02
- Other Operating Expenses Total
- 28.26
- Total Operating Expense
- 1625.23
- Operating Income
- 613.32
- Net Income Before Taxes
- 668.72
- Net Income
- 497.61
- Diluted Normalized EPS
- 108.07
- Period
- 2021
- Total Assets
- 3265.9
- Total Liabilities
- 872.86
- Total Equity
- 2393.04
- Tangible Book Valueper Share Common Eq
- 376.12
- Period
- 2021
- Cashfrom Operating Activities
- 427.33
- Cashfrom Investing Activities
- -468.84
- Cashfrom Financing Activities
- -1571.07
- Net Changein Cash
- -1612.58
- Period
- 2020
- Total Revenue
- 2151.65
- Selling/ General/ Admin Expenses Total
- 692.65
- Depreciation/ Amortization
- 101.86
- Other Operating Expenses Total
- 22.81
- Total Operating Expense
- 1639.57
- Operating Income
- 512.08
- Net Income Before Taxes
- 642.49
- Net Income
- 509.13
- Diluted Normalized EPS
- 106.14
- Period
- 2020
- Total Assets
- 4405.4
- Total Liabilities
- 1009.91
- Total Equity
- 3395.49
- Tangible Book Valueper Share Common Eq
- 583.22
- Period
- 2020
- Cashfrom Operating Activities
- 323.18
- Cashfrom Investing Activities
- 1530.32
- Cashfrom Financing Activities
- -163.52
- Net Changein Cash
- 1689.98
- Period
- 2019
- Total Revenue
- 2081.5
- Selling/ General/ Admin Expenses Total
- 665.24
- Depreciation/ Amortization
- 70
- Other Operating Expenses Total
- 22.59
- Total Operating Expense
- 1546.84
- Operating Income
- 534.66
- Net Income Before Taxes
- 659.91
- Net Income
- 429.05
- Diluted Normalized EPS
- 89.67
- Period
- 2019
- Total Assets
- 3939.99
- Total Liabilities
- 928.65
- Total Equity
- 3011.34
- Tangible Book Valueper Share Common Eq
- 487.19
- Period
- 2019
- Cashfrom Operating Activities
- 97.81
- Cashfrom Investing Activities
- 35.12
- Cashfrom Financing Activities
- -109.85
- Net Changein Cash
- 23.08
- Period
- 2024-12-31
- Total Revenue
- 537.99
- Selling/ General/ Admin Expenses Total
- 96.29
- Depreciation/ Amortization
- 14.8
- Other Operating Expenses Total
- 99.15
- Total Operating Expense
- 406.8
- Operating Income
- 131.19
- Net Income Before Taxes
- 172.44
- Net Income
- 127.6
- Diluted Normalized EPS
- 27.89
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 588.59
- Selling/ General/ Admin Expenses Total
- 100.76
- Depreciation/ Amortization
- 14.99
- Other Operating Expenses Total
- 87.86
- Total Operating Expense
- 414.33
- Operating Income
- 174.26
- Net Income Before Taxes
- 215.23
- Net Income
- 158.35
- Diluted Normalized EPS
- 34.61
- Period
- 2024-09-30
- Total Assets
- 4458.6
- Total Liabilities
- 707.73
- Total Equity
- 3750.87
- Tangible Book Valueper Share Common Eq
- 698.2
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 349.43
- Cashfrom Investing Activities
- -244.21
- Cashfrom Financing Activities
- -181.88
- Net Changein Cash
- -76.66
- Period
- 2024-06-30
- Total Revenue
- 562.86
- Selling/ General/ Admin Expenses Total
- 91.37
- Depreciation/ Amortization
- 14.6
- Other Operating Expenses Total
- 93.31
- Total Operating Expense
- 399.97
- Operating Income
- 162.89
- Net Income Before Taxes
- 202.62
- Net Income
- 150.71
- Diluted Normalized EPS
- 32.94
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 546.63
- Selling/ General/ Admin Expenses Total
- 75.11
- Depreciation/ Amortization
- 13.75
- Other Operating Expenses Total
- 92.75
- Total Operating Expense
- 370.95
- Operating Income
- 175.68
- Net Income Before Taxes
- 243.86
- Net Income
- 178.86
- Diluted Normalized EPS
- 39.09
- Period
- 2024-03-31
- Total Assets
- 4228.78
- Total Liabilities
- 633.24
- Total Equity
- 3595.54
- Tangible Book Valueper Share Common Eq
- 663.15
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 256.84
- Cashfrom Investing Activities
- 53.7
- Cashfrom Financing Activities
- -235.14
- Net Changein Cash
- 75.4
- Period
- 2023-12-31
- Total Revenue
- 539.97
- Selling/ General/ Admin Expenses Total
- 89.37
- Depreciation/ Amortization
- 17.55
- Other Operating Expenses Total
- 115.49
- Total Operating Expense
- 397.02
- Operating Income
- 142.95
- Net Income Before Taxes
- 175.94
- Net Income
- 129.98
- Diluted Normalized EPS
- 27.14
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Pfizer Technical
Moving Average
SMA
- 5 Day4367.57
- 10 Day4310.26
- 20 Day4280.42
- 50 Day4149.76
- 100 Day4422.81
- 300 Day4989.15
Pfizer Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Aurobindo Pharma
- 1201.85
- -15.15
- -1.24
- 1592.55
- 994.35
- 69803.65
- Pfizer
- 4412.6
- -43.65
- -0.98
- 6452.85
- 3742.9
- 20156.11
- Astrazeneca Pharma India
- 7839.35
- -108.25
- -1.36
- 9199
- 5180.6
- 19598.38
- Neuland Laboratories
- 11053.2
- -817.15
- -6.88
- 18089.55
- 5557
- 14181.14
- Unichem Laboratories
- 587.75
- 1.8
- 0.31
- 949.85
- 507.2
- 4137.03
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Aurobindo Pharma
- 21.07
- 2.36
- 14.22
- 12.72
- Pfizer
- 36.86
- 5.62
- 18.43
- 24.05
- Astrazeneca Pharma India
- 130.35
- 27.52
- 20.1
- 10.27
- Neuland Laboratories
- 69.97
- 9.3
- 17.29
- 14.2
- Unichem Laboratories
- -
- 1.77
- -2.1
- -3.99
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 19-May-25
- Audited Results & Dividend
- 31-Jan-25
- Quarterly Results
- 28-Oct-24
- Quarterly Results
- 29-Jul-24
- Quarterly Results
- 17-May-24
- Audited Results & Final Dividend
- 09-Feb-24
- Quarterly Results
- 28-Oct-23
- Quarterly Results
- 11-Aug-23
- Quarterly Results
- 15-May-23
- Audited Results & Final Dividend
- 09-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 28-Aug-24
- 09-Aug-24
- AGM
- 02-Apr-24
- 29-Feb-24
- POM
- 09-Jan-24
- 07-Dec-23
- POM
- 18-Aug-23
- 15-May-23
- AGM
- 26-Aug-22
- 20-May-22
- AGM
- 19-Aug-21
- 28-Jul-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 17-May-24
- 21-Aug-24
- 21-Aug-24
- 35
- 15-May-23
- 11-Aug-23
- 11-Aug-23
- 35
- 16-May-23
- 11-Aug-23
- 11-Aug-23
- 5
- 06-Sept-22
- 20-Sept-22
- 19-Sept-22
- 30
- 26-May-21
- -
- 11-Aug-21
- 30
- 27-May-21
- -
- 11-Aug-21
- 5


